A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
- Conditions
- Autosomal Dominant Retinitis PigmentosaEye Diseases, HereditaryRetinitisEye DiseasesRetinal DystrophiesRetinal DiseaseVision TunnelVision Disorders
- Interventions
- Other: Sham procedure
- Registration Number
- NCT04123626
- Lead Sponsor
- ProQR Therapeutics
- Brief Summary
This study evaluates the safety, tolerability and efficacy of QR-1123 injection in the eye (intravitreal; IVT) injections (one eye/unilateral) in subjects receiving a single dose or repeat doses. Single injections will be assessed in an open label way, and repeat injections will be assessed in a double-masked, randomized, sham-controlled fashion.
- Detailed Description
QR-1123 is an antisense oligonucleotide, designed to specifically target the mutant P23H messenger ribonucleic acid (mRNA) in order to reduce the expression of the P23H protein selectively, while preserving expression of the wild type (WT) rhodopsin (RHO) protein. It is hypothesized that the reduction of mutant P23H mRNA will reduce the deleterious effects of the dominant-negative protein and should result in increased function of WT rhodopsin protein in photoreceptors. Restoration of WT RHO function is expected to improve vision in patients with adRP due to the P23H mutation.
The study will comprise up to 8 single dose and repeat dose cohorts. Prior to initiating a higher single dose cohort and/or prior to initiating repeat dose cohort(s), available safety and efficacy data will be reviewed by the DMC.
In the single dose cohorts subjects will receive a single, unilateral IVT injection of QR-1123 in an open label fashion. In the repeat dose cohorts subjects will be randomized to receive either a unilateral IVT injection of QR-1123 every 3 months or a unilateral sham procedure every 3 months, in a double masked fashion. Subjects will be followed for safety, tolerability and efficacy for a total period of 12 months.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 11
- Male or female, ≥ 18 years of age.
- Clinical presentation consistent with adRP, based on ophthalmic examinations.
- Impairment on VF in the opinion of the Investigator, as determined by perimetry.
- A molecular diagnosis of autosomal dominant form of RP with the P23H mutation in the RHO gene, based on genetic analysis.
- A clear ocular media and adequate pupillary dilation to permit good quality fundus imaging, as assessed by the Investigator.
Main
- Presence of additional pathogenic mutations in genes (other than the P23H mutation in the RHO gene) associated with inherited retinal degenerative diseases or syndromes, based on genetic analysis (eg, Usher syndrome, Leber congenital amaurosis, etc).
- Presence of any significant ocular or non-ocular disease/disorder (including medication and laboratory test abnormalities) which, in the opinion of the Investigator and with concurrence of the Medical Monitor, may either put the subject at risk because of participation in the study, may influence the results of the study, or the subject's ability to participate in the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description QR-1123 Single dose - dose level 1 QR-1123 Open label Single dose cohort: dose level 1 Repeat dose cohort 1 Sham procedure Double-masked, randomized, sham controlled, Repeat dose cohort. Dose levels will be determined following DMC review of obtained safety and efficacy data. QR-1123 Single dose - dose level 4 QR-1123 Open label Single dose cohort: dose level 4 Repeat dose cohort 1 QR-1123 Double-masked, randomized, sham controlled, Repeat dose cohort. Dose levels will be determined following DMC review of obtained safety and efficacy data. QR-1123 Single dose - dose level 5 QR-1123 Open label Single dose cohort: dose level 5 QR-1123 Single dose - dose level 2 QR-1123 Open label Single dose cohort: dose level QR-1123 Single dose - dose level 3 QR-1123 Open label Single dose cohort: dose level 3
- Primary Outcome Measures
Name Time Method Incidence and Severity of non-ocular AEs up to 12 months Incidence and severity of non-ocular adverse events scored based on CTCAC in the study and fellow eye
Incidence and Severity of ocular AEs up to 12 months Incidence and severity of ocular adverse events scored based on CTCAC in the study and fellow eye
- Secondary Outcome Measures
Name Time Method Changes in DAC perimetry up to 12 months Changes in Dark adapted chromatic (DAC) perimetry
Changes in Static VF up to 12 months Changes in Static VF (Visual Field)
Assessment of systemic exposure after treatment with QR-1123 up to 12 months Serum levels of QR-1123
Changes in BCVA up to 12 months Changes in Best corrected visual acuity (BCVA)
Changes in LLVA up to 12 months Changes in Low-luminance visual acuity (LLVA)
Changes in Microperimetry up to 12 months Changes in Microperimetry
Changes in SD-OCT up to 12 months Changes in Spectral Domain-Optical Coherence Tomography
Changes in FST up to 12 months Changes in Full-field Stimulus Threshold (FST)
Changes in Full-field ERG up to 12 months Changes in Full-field Electroretinogram (ERG)
Trial Locations
- Locations (5)
Retina Foundation of the Southwest
🇺🇸Dallas, Texas, United States
Casey Eye Institute, OHSU
🇺🇸Portland, Oregon, United States
Sue Anschutz-Rogers Eye Center, University of Colorado - Dept. of Ophthalmology
🇺🇸Aurora, Colorado, United States
Shriners UK Ophthalmology - University of Kentucky
🇺🇸Lexington, Kentucky, United States
VitreoRetinal Associates
🇺🇸Gainesville, Florida, United States